Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer's Kerendia® (finerenone) was included in the European Society of Cardiology's (ESC) latest clinical guidance for patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). In its 2023 Focused Update of the 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure, Kerendia was recommended to reduce the risk of heart failure (HF) hospitalization in patients with CKD associated with T2D.1 The ESC listed thi.

Bayer's Kerendia® (finerenone) Included in Latest Focused Guideline Clinical Updates from European Society of Cardiology

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced it is further investing in MOONRAKER— its clinical development program to investigate Kerendia® (finerenone) as a potential treatment for heart failure (HF) — with the initiation of three additional investigator-sponsored collaborative studies.1,2,3,4 Recruiting approximately 15,000 patients, MOONRAKER is expected to be one of the largest heart failure (HF) study programs to date.1,2,3,4 The three additional studies are sponsored by CPC Clinical.

Bayer Expands Clinical Development Program Investigating Finerenone for Potential Treatment of Heart Failure

DURHAM, N.C. & MONHEIM, Germany--(BUSINESS WIRE)--Pairwise, a food and agriculture company known for bringing the first gene-edited food to the U.S. market, and Bayer today announced a new five-year, multi-million Dollar agreement focused on innovations in short-stature corn. This new program leverages Pairwise's Fulcrum™ platform and builds on the success of the companies' initial five-year collaboration for corn, soy, wheat, cotton, and canola. The upcoming collaboration between Pairwise and.

Pairwise, Bayer Build on Successful Gene Editing Partnership With New Five-Year, Multi-Million Dollar Collaboration to Further Advance Short-Stature Corn

GHENT, Belgium--(BUSINESS WIRE)--Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced the appointment of Dieter Weinand as Independent Chairman of its Board of Directors. Mr. Weinand brings with him a wealth of experience with more than 35 years in the pharmaceutical industry and over 25 years as the leader of geographic and strategic business units and drug commercialization efforts across global organizations, including seve.

Confo Therapeutics Appoints Dieter Weinand, Former CEO of Bayer Pharmaceuticals, as Independent Chairman

Kroger

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, one of the country's largest life-sciences companies, announced today its campaign to remind rural America to “Take Care, Now” and help alleviate care deserts in rural America, areas significantly impacted by both food insecurity and limited access to healthcare. Today, 90 percent of counties with the highest food insecurity rates are rural1 and rural communities represent nearly two-thirds of primary care health professional shortage areas in the country.

Bayer and Kroger Team to Help Improve Access to Health and Nutrition in Rural America

Bayer said an experimental stem cell therapy developed by its U.S. subsidiary BlueRock had shown signs of easing Parkinson's disease symptoms in an early 12-patient trial.

Bayer says Parkinson's stem cell therapy improves symptoms in initial trial

Alico

Capital City Bank Group

ALCO, BAYRY and CCBG have been added to the Zacks Rank #5 (Strong Sell) List on August 25, 2023.

New Strong Sell Stocks for August 25th

SAN FRANCISCO & BASEL, Switzerland--(BUSINESS WIRE)--Mahana Therapeutics, a leading provider of prescription digital therapeutics, announced today that the company has entered into a multi-million-dollar distribution and marketing partnership with the Consumer Health division of Bayer to commercialize digital therapeutics. Earlier this year, Bayer announced the launch of a new business unit focused on delivering new digitally enabled precision health products to market. Bayer is prioritizing de.

Mahana Therapeutics Signs Agreement with Consumer Health Division of Bayer to Commercialize Digital Therapeutics

Bayer reporting disappointing second quarter results with declining sales and lowered the guidance for fiscal 2023. The company is continuing to struggle and total debt increased again and management is now expecting no free cash flow in 2023. But over the long run, Bayer should profit from several headwinds and is operating in three segments with huge addressable markets.

Bayer: Still A Strong Buy Despite Lowered Guidance

WHIPPANY, N.J.--(BUSINESS WIRE)--In the aftermath of the devastating fires that have affected the Maui community, Bayer stands in solidarity with those impacted and offers heartfelt condolences for the losses endured. With roots spanning more than 50 years in Maui County, Bayer is firmly committed to providing immediate relief and sustained support for recovery and rebuilding. Guided by its vision, 'Health for All, Hunger for None,' Bayer will contribute $500,000 to relief efforts on the island.

Bayer Donates $500K to Support Maui Community After Devastating Fires

Bayer Aktiengesellschaft (OTCPK:BAYZF) Q2 2023 Earnings Call Transcript August 8, 2023 8:00 AM ET Company Participants Oliver Maier - Head of IR Bill Anderson - CEO Wolfgang Nickl - CFO Rodrigo Santos - President, Crop Science Division Stefan Oelrich - President, Pharmaceuticals Division Heiko Schipper - President, Consumer Health Division Conference Call Participants Michael Leuchten - UBS Richard Vosser - JPMorgan James Quigley - Morgan Stanley Peter Verdult - Citigroup Sachin Jain - Bank of America Vincent Andrews - Morgan Stanley Emily Field - Barclays Florent Cespedes - Societe Generale Steve Byrne - Bank of America Operator Ladies and gentlemen, thank you for standing by. Welcome to Bayer's Investors and Analyst Conference Call on the Second Quarter 2023 Results.

Bayer Aktiengesellschaft (BAYZF) Q2 2023 Earnings Call Transcript

Bayer (BAYRY) misses earnings and sales estimates in the second quarter of 2023 due to lower volumes and decreased prices for glyphosate-based products. Management lowers its guidance.

Bayer (BAYRY) Q2 Earnings Miss Estimates, '23 Outlook Lowered

ST. LOUIS--(BUSINESS WIRE)--While America has sharks on its mind, there's another tiny ravenous predator causing damage of their own on our farms — the corn rootworm. These “sharks of the Midwest” attack underground and their sheer numbers make them difficult to control. These pests cause up to $2 billion dollars1 of damage annually to the nation's corn crop. That's taking money away from farmers and, ultimately, food from our plate. On the tail end of the week-long TV block dedicated to the ic.

The Terror is Hatching: Bayer Unveils Upcoming “Rootworm Week”

NORTHAMPTON, MA / ACCESSWIRE / August 2, 2023 / Bayer As no one can overcome every challenge alone, we establish crop value-chain partnerships to provide smallholder farmers with high-quality inputs, agronomic knowledge, cost-effective financing and risk mitigation solutions, as well as market access to sell their products. These include collaborations with government research institutes, NGOs and international financial institutions.

Bayer Collaborates in Value-Chain Partnerships

Bayer (BAYRY) lowers its full-year financial performance guidance for 2023 and reports preliminary earnings results for the second quarter of 2023.

Bayer (BAYRY) Cuts 2023 Outlook, Reports Preliminary Q2 Results

WHIPPANY, N.J.--(BUSINESS WIRE)--For the fifth consecutive year, Bayer U.S. has been awarded and recognized by The Disability Equality Index (DEI) as a “Best Place to Work for Disability Inclusion.” This is the third year that Bayer has received a top score of 100% in the DEI, which is the most comprehensive disability inclusion tool designed and embraced by both business leaders and disability advocates across the country. As part of Bayer's inclusive vision, “Health for All, Hunger for None,”.

Bayer Earns Top Score on 2023 Disability Equality Index

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, one of the country's largest life-sciences companies, announced today it's heading back to the farm and renewing its multi-year partnership with five-time entertainer of the year Luke Bryan. They are teaming up for their annual Here's to the Farmer campaign benefitting Feeding America, with the company joining Bryan on his 2023 Farm Tour as presenting sponsor. Continuing a partnership that began in 2015, this year's campaign celebrates America's hard-work.

Bayer and Luke Bryan Reunite for Annual #HerestotheFarmer Campaign in Support of Feeding America and Rural Communities

Drugmaker Bayer said on Wednesday that initial testing on humans showed that its experimental stem cell therapy to treat Parkinson's disease was well-tolerated and that transplanted cells survived in patients' brains.

Bayer: Phase I trial results from Parkinson's cell therapy positive

Bayer subsidiary BlueRock has become the first company to report initial success treating Parkinson's disease in humans using an experimental stem cell therapy, the drugmaker said on Wednesday.

(OFFICIAL) Bayer claims early lead in Parkinson's stem cell therapy

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in radiology, has initiated the Phase III clinical development program called QUANTI, aiming to evaluate the safety and efficacy of gadoquatrane, an investigational extracellular macrocyclic gadolinium-based contrast agent (GBCA) for use in magnetic resonance imaging (MRI). Gadoquatrane is a highly stable MRI contrast agent featuring high relaxivity being studied to evaluate the potential of a substantially lower gadolinium (Gd) dose for p.

Bayer initiates Phase III studies with investigational contrast agent gadoquatrane

Bayer reported mixed Q1 2023 results, matching analyst consensus expectations with regard to profitability and earnings, but missing on topline and guidance. Long term, Bayer remains well-positioned for growth: Bayer's Crop Science Innovation Summit highlighted an ambitious innovation pipeline valued at approximately €30 billion. Anchored on adjusted EPS estimates through 2025, in line with analyst consensus, I see close to ~55% upside; and accordingly, I reiterate a "Strong Buy" recommendation.

Bayer: Easy Deep Value Pitch

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that Ultravist® (iopromide)-300, -370, its iodine-based contrast agent, has been approved by the U.S. Food and Drug Administration (FDA) for contrast-enhanced mammography (CEM) – making it the only contrast agent approved for this indication. The product can be used to visualize known or suspected lesions of the breast in adults, as an adjunct to mammography and/or ultrasound. CEM is an emerging modality that combines digital mammography wi.

FDA approves Bayer's Ultravist® (iopromide) injection for contrast-enhanced mammography

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the initiation of FINE-ONE, a global, multicenter, randomized, placebo-controlled, double-blind, parallel-group Phase III study to evaluate the efficacy and safety of a new investigational use of finerenone versus placebo in adults with chronic kidney disease (CKD) and type 1 diabetes (T1D). The primary objective of the study is to demonstrate efficacy of finerenone over placebo in reducing urine albumin to creatinine ratio (UACR) over 6 mo.

Bayer to Investigate Finerenone in Phase III Study in Adults With Chronic Kidney Disease Associated With Type 1 Diabetes

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, one of the country's leading life-sciences companies, today announced its new Senior Bayer Representative and President of Bayer U.S. Sebastian Guth, Bayer's President of Pharmaceuticals Americas, assumes this leadership role, which oversees all Bayer U.S. operations, on June 30, 2023. Guth, who has been with Bayer for 17 years, will retain leadership of the Pharmaceuticals business for the U.S., a critical growth market for the company, and Canada. Bayer.

Bayer Announces Senior Bayer Representative and President of Bayer U.S.

Bayer AG agreed on Thursday to pay $6.9 million to settle claims by New York Attorney General Letitia James that it misled consumers by advertising Roundup weedkiller as safe.

News for Bayer AG Stock (BAYRY)